ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis
- PMID: 20375998
- DOI: 10.1038/clpt.2009.252
ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis
Abstract
Epidermal necrolysis (EN)--either Stevens-Johnson syndrome (SJS) or toxic EN (TEN)--is a severe drug reaction. We constructed and evaluated a specific algorithm, algorithm of drug causality for EN (ALDEN), in order to improve the individual assessment of drug causality in EN. ALDEN causality scores were compared with those from the French pharmacovigilance method in 100 cases and the case-control results of the EuroSCAR study. Scores attributed by ALDEN segregated widely. ALDEN pointed to a "probable" or "very probable" causality in 69/100 cases as compared to 23/100 with the French method (P < 0.001). It scored "very unlikely" causality for 64% of medications vs. none with the French method. Results of ALDEN scores were strongly correlated with those of the EuroSCAR case-control analysis for drugs associated with EN (r = 0.90, P < 0.0001), with probable causality being reported in 218/329 exposures. ALDEN excluded causality in 321 drugs that the case-control analysis had described as "probably not associated" and in 22/233 drugs that had been described as inconclusive exposures. Being more sensitive than a general method, ALDEN, which correlates well with case-control analysis results, can be considered a reference tool in SJS/TEN.
Similar articles
-
Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.Pediatrics. 2009 Feb;123(2):e297-304. doi: 10.1542/peds.2008-1923. Epub 2009 Jan 19. Pediatrics. 2009. PMID: 19153164
-
Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications.Pharmacoepidemiol Drug Saf. 2012 Mar;21(3):289-96. doi: 10.1002/pds.2276. Epub 2011 Dec 5. Pharmacoepidemiol Drug Saf. 2012. PMID: 22139991
-
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.J Am Acad Dermatol. 2008 Jan;58(1):25-32. doi: 10.1016/j.jaad.2007.08.036. Epub 2007 Oct 24. J Am Acad Dermatol. 2008. PMID: 17919772
-
Stevens-Johnson syndrome and toxic epidermal necrolysis: what do we know?Ther Drug Monit. 2010 Dec;32(6):669-72. doi: 10.1097/FTD.0b013e3181f2f24f. Ther Drug Monit. 2010. PMID: 20844465 Review.
-
Liver Injury in Immune Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Five New Classification Types.J Clin Transl Hepatol. 2025 Apr 28;13(4):339-357. doi: 10.14218/JCTH.2024.00402. Epub 2025 Jan 17. J Clin Transl Hepatol. 2025. PMID: 40206276 Free PMC article. Review.
Cited by
-
Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020.Front Med (Lausanne). 2022 Aug 24;9:949520. doi: 10.3389/fmed.2022.949520. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36091694 Free PMC article.
-
Risk of toxic epidermal necrolysis and Stevens-Johnson syndrome associated with benzodiazepines: a population-based cohort study.Eur J Clin Pharmacol. 2015 Jun;71(6):759-766. doi: 10.1007/s00228-015-1850-y. Epub 2015 May 5. Eur J Clin Pharmacol. 2015. PMID: 25939709
-
Culprit Medications and Risk Factors Associated with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case-Control Study.Am J Clin Dermatol. 2022 Mar;23(2):257-266. doi: 10.1007/s40257-021-00661-0. Epub 2022 Feb 4. Am J Clin Dermatol. 2022. PMID: 35119606 Free PMC article.
-
The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study.Indian Dermatol Online J. 2022 Jan 24;13(1):23-31. doi: 10.4103/idoj.idoj_530_21. eCollection 2022 Jan-Feb. Indian Dermatol Online J. 2022. PMID: 35198464 Free PMC article.
-
HLA-B*57:01/Carbamazepine-10,11-Epoxide Association Triggers Upregulation of the NFκB and JAK/STAT Pathways.Cells. 2023 Feb 21;12(5):676. doi: 10.3390/cells12050676. Cells. 2023. PMID: 36899812 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials